Want to see BVS full AI Analyst Report?
BVS Stock Chart & Stats
$10.52
-$0.12(-1.26%)
At close: 4:00 PM EST
$10.52
-$0.12(-1.26%)
Day’s Range― - ―
52-Week Range$5.81 - $12.23
Previous CloseN/A
Volume116.12K
Average Volume (3M)715.42K
Market Cap
$1.01B
Enterprise Value$814.80M
Total Cash (Recent Filing)$35.85M
Total Debt (Recent Filing)$272.08M
Price to Earnings (P/E)28.6
Beta0.75
Next Earnings
Aug 11, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding67,748,050
10 Day Avg. Volume734,283
30 Day Avg. Volume715,417
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.69
Price to Sales (P/S)0.87
P/FCF Ratio6.94
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit2.09
Enterprise Value/Ebitda7.89
Forecast
1Y Price Target
$15.00Price Target Upside42.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)$605.76M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained TTM operating and free cash flow gives durable funding for R&D, commercial expansion and debt reduction. High cash conversion reduces refinancing risk, supports reinvestment plans, and underpins margin resilience across procedure-volume cycles.
De‑levering ProgressMaterial reduction in leverage materially de‑risks the capital structure and increases financial flexibility. Lower net leverage reduces interest burden, improves covenant headroom and makes it easier to fund international expansion and targeted investments without jeopardizing liquidity.
Regulatory/Market AccessReclassification to Class II lowers regulatory hurdles and can expand adoption and reimbursement clarity for Exogen. Over time this structural change should ease commercialization, reduce compliance costs, and improve the long‑term revenue potential of the ultrasound bone‑healing franchise.
Bears Say
Uneven Revenue MomentumInconsistent top‑line trends weaken predictability of earnings and cash flow. Durable margin expansion depends on sustained procedure volumes and stable distributor execution; absent consistent revenue growth, recent profitability and cash improvements could slip back in future cycles.
Early‑stage Growth RiskKey growth initiatives (PNS, PRP, Ultrasonics) are still early and require clinical validation, training and time to scale. If adoption or salesforce effectiveness lags, expected revenue diversification and margin uplift may be delayed, pressuring returns on incremental investments.
One‑time Benefit VisibilityA one‑time rebate boosted Q1 margins and cash flow, obscuring the recurring operating base. Reliance on non‑recurring items reduces forecast visibility and could overstate sustainable margins and cash generation if similar adjustments do not recur.
Bioventus News
BVS FAQ
What was Bioventus, Inc.’s price range in the past 12 months?
Bioventus, Inc. lowest stock price was $5.81 and its highest was $12.23 in the past 12 months.
What is Bioventus, Inc.’s market cap?
Bioventus, Inc.’s market cap is $1.01B.
When is Bioventus, Inc.’s upcoming earnings report date?
Bioventus, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 33 days.
How were Bioventus, Inc.’s earnings last quarter?
Bioventus, Inc. released its earnings results on May 06, 2026. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.069 by $0.081.
Is Bioventus, Inc. overvalued?
According to Wall Street analysts Bioventus, Inc.’s price is currently Undervalued.
Does Bioventus, Inc. pay dividends?
Bioventus, Inc. does not currently pay dividends.
What is Bioventus, Inc.’s EPS estimate?
Bioventus, Inc.’s EPS estimate is 0.22.
How many shares outstanding does Bioventus, Inc. have?
Bioventus, Inc. has 67,748,050 shares outstanding.
What happened to Bioventus, Inc.’s price movement after its last earnings report?
Bioventus, Inc. reported an EPS of $0.15 in its last earnings report, beating expectations of $0.069. Following the earnings report the stock price went up 2.247%.
Which hedge fund is a major shareholder of Bioventus, Inc.?
Currently, no hedge funds are holding shares in BVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (42.59% Upside)
$15.00 (42.59% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 359.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▲ 18.3%
Last 30 Days ▲ 18.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.47%
12-Months-Change
Fundamentals
Return on Equity
16.27%
Trailing 12-Months
Asset Growth
-5.91%
Trailing 12-Months
Company Description
Bioventus, Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Company Deck
BVS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong financial momentum: solid revenue growth (+7%), robust adjusted EBITDA expansion (+24%), improved margins and materially stronger cash flow (+$28M YoY), along with raised EPS and cash guidance. Management is accelerating targeted investments (primarily into PNS, PRP, Ultrasonics and International) and added senior leadership to scale new businesses. Offsetting items include a one-time favorable rebate that boosted Q1 results, near-term margin volatility as investments ramp, early-stage nature of new growth drivers, distributor inventory/timing headwinds in Pain, and a still-material debt balance ($272M) that remains a focus. Overall, the positives (growth, profitability, cash generation and proactive reinvestment) outweigh the manageable near-term challenges.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$15.00
▲(42.59% Upside)
Technical Analysis
Ownership Overview
32.13% Insiders
8.71% Mutual Funds
48.92% Other Institutional Investors
0.10% Public Companies and
Individual Investors